Braxia Scientific treats depression, suicidality, and related mental health conditions.
Braxia is a company of tomorrow, focused on ketamine treatment and psychedelic medicine for advanced mental health treatments.
Why ketamine mental health treatment?
Ketamine is a safe and proven effective treatment for adults with depression, suicidality and related disorders. Ketamine is legally available administered under trained medical supervision. Braxia represents Best Practices in the implementation of ketamine in persons who are eligible.
Our Focus.
Addressable Market.
$8T
Global economic cost
Estimated cost to the global economy due to depressive disorders in U.S. dollars.
$238B
Estimated addressable market size
Estimated market size for anxiety disorder and depression treatments in U.S. dollars.
$16B
Annual U.S. Spend
Estimated annual expenditure in the United States on mental health treatments and ancillary services in U.S. dollars.
News Releases.
Braxia Scientific Reports a 26% Increase in Total Treatment Volumes in F2023 and an 87% Increase in Treatments at Newly Expanded Ottawa Clinic
Company Taking Strategic Actions to Prioritize Clinic Expansion, Enhance Operational Effectiveness and Right Size Cost Structure. TORONTO, ONTARIO Monday June 12, 2023 – Braxia Scientific Corp. (“Braxia”, or the“Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with mentalhealth clinics providing innovative ketamine and psilocybin treatments for depression and relateddisorders, is pleased to report treatment volumes across its clinics increased 26.2% to 3,516 from2,785 treatments on a year-over-year basis in Fiscal 2023. The Company continues to experienceincreased demand across all of it 5 clinics. At its new Ottawa clinic, treatment volumes increased87.2% to 571 from 305 treatments on a year-over-year basis following the completion of constructionand opening of its expanded purpose-built clinic in late 2022. Additionally, its Kitchener-Waterlooclinic, opened in mid-2022, continues to see rapid increases in treatment volume, reaching 214treatments in its first 8 months of operation.“Over...
Braxia Scientific Reports Fiscal 2023 Financial Results
Braxia Health ketamine treatments up 26% YoY in 2023 and revenue up 27% YoY Company completes dosing of final participant in Phase 2, multi-dose Psilocybin trial, results expected to be published prior to end of 2023 Company reviewing financing options, strategic partnerships and further cost reductions and organizational changes as required TORONTO, ONTARIO July 31, 2023 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and twelve months ended March 31, 2023. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for...
Braxia Scientific Reports Q3 2023 Financial Results and Provides Update on Acquisition Under LOI with Irwin Naturals
Braxia Health ketamine treatments up 29% YoY in Q3 2023 and revenue up 50.5% YoY TORONTO, ONTARIO Wednesday March 1, 2023 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the third quarter ended December 31, 2023. The Company also provided an update on the proposed acquisition of the Company by Irwin Naturals Inc. (CSE: IWIN) (OTCQB: IWINF) (FSE: 97X) ("Irwin") as outlined in the non-binding Letter of Intent ("LOI") announced January 27, 2023. Complete financial statements along with related management discussion and analysis and the LOI can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system...
Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement
TORONTO, ONTARIO February 27, 2023 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023 (the “LIFE Offering”), resulting in the issuance of 13,658,524 units of the Company (each a “Unit”) at a price of $0.055 per Unit for aggregate proceeds of $751,218.83 (the “LIFE First Tranche”). Each Unit consists of one common share of the Company (each a “Common Share”) and one Common Share purchase warrant (each a “Warrant”). Each Warrant entitles its holder to purchase one additional Common Share at an exercise price of $0.07 for a period of 36 months from the date of issue....